Broad integration of mechanistic pathways
Sections 2–3 connect established DNA-damage and ROS mechanisms with senescence, ferroptosis, pyroptosis, immunogenic cell death, and PD-L1 regulation.
↳ Sections 2–3
Abstract
Doxorubicin (DOX) constitutes the major constituent of anti-cancer treatment regimens currently in clinical use. However, the precise mechanisms of DOX's action are not fully understood. Emerging evidence points to the pleiotropic anticancer activity of DOX, including its contribution to DNA damage, reactive oxygen species (ROS) production, apoptosis, senescence, autophagy, ferroptosis, and pyroptosis induction, as well as its immunomodulatory role. This review aims to collect information on the anticancer mechanisms of DOX as well as its influence on anti-tumor immune response, providing a rationale behind the importance of DOX in modern cancer therapy.
Key Claims
Primary findingSupported
Emerging evidence points to the pleiotropic anticancer activity of DOX, including its contribution to DNA damage, reactive oxygen species production, apoptosis, senescence, autophagy, ferroptosis, and pyroptosis induction, as well as its immunomodulatory role.
broadly cited synthesis across heterogeneous experimental systems, with individual mechanisms remaining context-dependent
Abstract
SecondarySupported
DOX not only has direct cytotoxic effects on cancer cells, but also contributes to the elimination of cancer cells via the activation of immune CD8+ T-cell responses.
preclinical and limited clinical evidence supports immune involvement without establishing uniform effects across cancers
Section 4, Conclusions
SecondarySupported
Although several DOX nanoformulations have been shown to increase the therapeutic output in comparison to standard preparations, they still face obstacles such as suboptimal diffusion and permeation properties, sophisticated release patterns, immunogenic responses, and undesirable interactions with serum proteins.
qualified formulation claim reflects mixed translational evidence and explicitly acknowledges unresolved barriers
Section 4, Conclusions
SecondarySupported
DOX exerts its effect on normal cells, leading to the development of life-threatening side effects including myelosuppression, nephrotoxicity, and cardiotoxicity.
well-established toxicity claim is consistently presented, though retained from a single enumerated assessment
Section 4, Conclusions
Derived from the full evaluation — not a separate score.
Strengths · Limitations
Strengths
Contradictory findings remain visible
The review explicitly reports disagreement over TP53, lipid peroxidation, and the dual or context-dependent roles of senescence and autophagy rather than presenting false consensus.
↳ Sections 2.2–2.4
Figures clarify dense molecular cascades
Figures 1–3 map DNA-damage responses, ROS-mediated apoptosis, and antitumor immune responses, supporting navigation of otherwise acronym-dense sections.
↳ Figures 1–3
Limitations
Source selection remains undocumented
No methods section describes databases, search terms, date limits, inclusion criteria, or how evidence was prioritized across 278 references.
↳ Sections 1–4; no review-methods section
Synthesis offers limited original advance
The review organizes established and emerging mechanisms but does not resolve the identified controversies or develop a framework that changes their interpretation.
↳ Abstract; Conclusions
Therapeutic evidence lacks explicit hierarchy
Cell-line, animal, and clinical findings are often presented consecutively without a formal hierarchy, limiting the clinical interpretability of combination and delivery claims.
↳ Section 3; Conclusions
Nabu Commentary
Sections 2–3 provide extensive citation coverage and connect conventional DNA-damage pathways with newer cell-death and immune mechanisms. The strongest execution feature is the visible treatment of conflicting evidence, including TP53 dependence, lipid peroxidation, and context-specific autophagy or senescence. The absence of a source-selection method and evidence hierarchy keeps the review in the competent-reference range rather than the high-quality synthesis range. The delivery recommendation in the Conclusions is also more categorical than the surrounding account of approved conventional use and unresolved nanoformulation barriers.
Check another paper
Author Note / Field Feedback
Nabu’s assessment, alongside the field’s view.
Are you an author of this paper?
Dimension breakdown
Study Quality
Sound3.1
Confidence mediumContribution
2.8
The review consolidates classical cytotoxic mechanisms, newer cell-death pathways, and immune modulation in one account. Its advance remains incremental because the Conclusions recapitulate these mechanisms without resolving disputes or proposing an integrative framework.
Abstract; Sections 2–4
“Emerging evidence points to the pleiotropic anticancer activity of DOX”
Methodological Rigour
3.0
The mechanism-by-mechanism structure is traceable, extensively cited, and includes contradictory findings. No search strategy, selection criteria, date range, or evidence-assessment process is reported for the broad synthesis.
Sections 1–4; no review-methods section
“Here we review new insights into the DOX mode of action”
Reporting
3.7
Section headings and Figures 1–3 make the molecular pathways followable, and uncertainty is usually expressed with calibrated language. The conclusion that DOX must use a special delivery vehicle is more categorical than the surrounding formulation discussion.
Figures 1–3; Conclusions, p. 17
“DOX must be loaded into a special vehicle and delivered to specific tumor sites”
Positioning
3.4
The paper engages extensive foundational and recent literature and explicitly discusses conflicting findings on TP53, lipid peroxidation, autophagy, and formulation barriers. Clinical, animal, and cell-line evidence is nevertheless juxtaposed without a formal hierarchy of therapeutic relevance.
Sections 2.2–3; Conclusions
“Inconsistency exists on the role of TP53 in DOX-induced apoptosis.”
Reliability
Caveats4 of 4 checks
Internal CoherenceNoted
The mechanistic synthesis is generally internally consistent, but one conclusion-level delivery recommendation is more categorical than the preceding evidence warrants. This affects interpretation rather than the reliability of underlying data.
Research ConductClean
The article generates no original human or animal data and appropriately states that institutional review is not applicable. Funding and conflict-of-interest declarations are present, with no conduct concern identified.
Flags: 2 declared / 5 total
Reference IntegrityClean
283 of 283 checkable references verified
284 references in manuscript 1 have no canonical index record — counted, but not index-checkable 1 reference confirmed by manual review
References not verified automatically are resolved manually within 24 hours.
Post-Publication RecordClean
No retraction or expression of concern found in Crossref (includes Retraction Watch).
Last checked: 17 Oct 2026
Sources: Crossref (incl. Retraction Watch) ✓
Readiness
Where this paper’s evidence sits on the path from initial observation to real-world use.
Mechanistic
The cited evidence includes approved liposomal formulations and a clinical immune-induction study, but much of the mechanistic and combination evidence remains preclinical. The review supplies no implementation criteria or operational recommendations.
Section 3, including refs. 210 and 233–275; Conclusions
“force their in-depth in vitro and in vivo investigations”
AI-generated, human-governed. Something look off? Contact us to request a review.